A Phase 1 interventional study of ENZ215 and EU Sourced Prolia in Healthy Male Subjects, sponsored by Enzene Biosciences Ltd.. Completed at 2 sites in 2 countries. Open to male participants aged 28 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by Enzene Biosciences Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, double-blind, three-arm, parallel-group, single-dose study to demonstrate bioequivalence of ENZ215 and EU- and US-sourced Prolia after a single 60-mg dose administered subcutaneously in healthy adult male volunteers.
Approximately 207 subjects will be enrolled into 3 groups (69 in each group) in parallel. The subjects may be enrolled in multiple groups at the site. All eligible subjects will be assigned to one of the three treatment groups in 1:1:1 ratio i.e. ENZ215 or US-sourced Prolia® or EU-sourced Prolia® to enter into the study period of 39 weeks. The study duration will be approximately 16 months (i.e. 6 months of recruitment period, 4 weeks of screening period and approximately 39 weeks (270 days) of study period).
Each subject will be required to visit the site for a total of 20 visits: visit 1 - screening visit, visit 2 - day 0 to day 2, visit 3 - day 3, visit 4 - day 4, visit 5 - day 5, visit 6 - day 6, visit 7 - day 8, visit 8 - day 10, visit 9 - day 12, visit 10 - day 16, visit 11 - day 21, visit 12 - day 28 (week 4), visit 13 - day 42 (week 6), visit 14 - day 63 (week 9), visit 15 - day 90 (week 13), visit 16 - day 119 (week 17), visit 17 - day 147 (week 21), visit 18 - day 180 (week 26), visit 19 day - 224 (week 32), and visit 20 - day 270 (week 39). A window period of ±1 day is allowed for visit 12 (day 28), window period of ±3 days are allowed from day 42 (week 6) to day 180 (week 26), A window period of ±5 days are allowed from day 224 (week 32) to day 270 (week 39).
End of Study Assessment will be performed on day 270 (week 39) or at the time of early discontinuation of the subject.
Enzene Biosciences Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subjects will be included in the study based on the following criteria:
Willing for multiple sampling and admission at the phase 1 study site day before dosing.
Note: QTc interval will be calculated using the Bazette and Fridericia formula.
Female partners should use hormonal or non-hormonal method of contraception. (No restrictions are required for a vasectomised male provided his vasectomy has been performed 4 months or more prior to the first dosing. A male who has been vasectomised less than 4 months prior to the first dosing must follow the same restrictions as a non-vasectomised male).
EXCLUSION CRITERIA
The subjects will be excluded from the study based on the following criteria:
Participating or has received any drug (or is currently using an investigational device) within 30 days before receiving the study drug, or at least 10 times the respective elimination halflife (whichever period is longer) *
* For monoclonal antibody refer exclusion criteria number 18 and 19
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ENZ215 Injection:- 60 mg Denosumab (ENZ215) will be administered subcutaneously on day 1.
Biological: ENZ215
EU sourced Prolia Injection:- 60 mg Denosumab (EU sourced Prolia) will be administered subcutaneously on day 1.
Biological: EU Sourced Prolia
US sourced Prolia Injection:- 60 mg Denosumab (US sourced Prolia) will be administered subcutaneously on day 1.
Biological: US Sourced Prolia
healthy volunteers receive ENZ215 (60mg) once
healthy volunteers receive Denosumab (60mg) once
healthy volunteers receive Denosumab (60mg) once
Maximum Observed Drug Concentration (Cmax) of ENZ215 and EU- and US-sourced Prolia®
A total of twenty four blood PK samples of 2.5 mL each were collected from each subject in the study. Pre-dose sample were collected within 30 minutes prior to IP administration. Post-dose samples up to Day 2 were collected within ± 10 minutes, within ± 2 hours from Day 3 to Day 21, within ± 1 day on Day 28, within ± 3 days from Day 42 to Day 180 and within ±5 days from Day 224 to Day 270. Serum concentrations of denosumab were measured at central laboratory by a validated analytical method.
Time frame: 270 days
Area Under the Drug Concentration-time Curve From Day 0 to Day 270 (AUC0-t) of ENZ215, EU- and US-sourced Prolia®. and EU- and US-sourced Prolia®
A total of twenty four blood PK samples of 2.5 mL each were collected from each subject in the study. Pre-dose sample were collected within 30 minutes prior to IP administration. Post-dose samples up to Day 2 were collected within ± 10 minutes, within ± 2 hours from Day 3 to Day 21, within ± 1 day on Day 28, within ± 3 days from Day 42 to Day 180 and within ±5 days from Day 224 to Day 270. Serum concentrations of denosumab were measured at central laboratory by a validated analytical method.
Time frame: 270 days
Area Under the Drug Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of ENZ215, EU- and US-sourced Prolia®. and EU- and US-sourced Prolia®
A total of twenty four blood PK samples of 2.5 mL each were collected from each subject in the study. Pre-dose sample were collected within 30 minutes prior to IP administration. Post-dose samples up to Day 2 were collected within ± 10 minutes, within ± 2 hours from Day 3 to Day 21, within ± 1 day on Day 28, within ± 3 days from Day 42 to Day 180 and within ±5 days from Day 224 to Day 270. Serum concentrations of denosumab were measured at central laboratory by a validated analytical method.
Time frame: 270 days
Partial Area Under the Drug Concentration-time Curve From Time 0 (Pre-dose) to Day 28
AUC0-28 days were compared between ENZ215 and Prolia® using tests after log-transformation wherever appropriate.
Time frame: 28 days
Time to Reach Cmax (Tmax)
The non-parametric analysis was used for the comparison of tmax between ENZ215 and Prolia®.
Time frame: 270 days
Terminal Elimination Half-life (t1/2)
t1/2 was compared between ENZ215 and Prolia® using tests after log-transformation wherever appropriate.
Time frame: 270 days
Apparent Systemic Clearance (CL/F)
CL/F was compared between ENZ215 and Prolia® using tests after log-transformation wherever appropriate.
Time frame: 270 days
Area Under the Effect Curve (AUEC) From Time 0 to Day 270 for Serum CTX-1 Percent Inhibition Percent Inhibition
The AUEC was calculated as the area under the effect curve from baseline until CTX-1 values return to baseline for the first time. A total of sixteen (16) blood samples for serum CTX-1 estimation of 3.5 mL each was collected from each subject in the study. For CTX-1, blood samples were collected at the same time and after a minimum of 10 hours of fasting.
Time frame: 270 days
Number of Subjects Who Developed Denosumab Neutralizing Antibodies and Antidrug Antibodies. Antibodies
A total of 10 blood Immunogenicity assessment samples of 5.0 mL for NAb and ADA were collected from each subject in the study. The frequency and percentage of positive ADA or NAb result was provided. The proportion of positive ADA or NAb in each treatment group was compared using chi-square or Fisher's exact tests. The p-value, relative risk, and corresponding 95% CI was presented.
Time frame: 270 days
Incidence of Adverse Events
Adverse events and SAEs as and when occurred, were properly recorded, evaluated, managed, and reported from signing informed consent till end of Study Assessment visit. All AEs were summarized using appropriate medical coding dictionary.
Time frame: 270 days
| Milestone | ENZ215 | EU Sourced Prolia | US Sourced Prolia |
|---|---|---|---|
| Started | 68 | 69 | 70 |
| Completed | 66 | 67 | 67 |
| Not completed | 2 | 2 | 3 |
A total of twenty four blood PK samples of 2.5 mL each were collected from each subject in the study. Pre-dose sample were collected within 30 minutes prior to IP administration. Post-dose samples up to Day 2 were collected within ± 10 minutes, within ± 2 hours from Day 3 to Day 21, within ± 1 day on Day 28, within ± 3 days from Day 42 to Day 180 and within ±5 days from Day 224 to Day 270. Serum concentrations of denosumab were measured at central laboratory by a validated analytical method.
| ng/ml | ENZ215 | EU Sourced Prolia | US Licensed Prolia |
|---|---|---|---|
| Maximum Observed Drug Concentration (Cmax) of ENZ215 and EU- and US-sourced Prolia® | 7662.99 ± 32.6 | 7742.64 ± 23.2 | 8033.14 ± 24.9 |
A total of twenty four blood PK samples of 2.5 mL each were collected from each subject in the study. Pre-dose sample were collected within 30 minutes prior to IP administration. Post-dose samples up to Day 2 were collected within ± 10 minutes, within ± 2 hours from Day 3 to Day 21, within ± 1 day on Day 28, within ± 3 days from Day 42 to Day 180 and within ±5 days from Day 224 to Day 270. Serum concentrations of denosumab were measured at central laboratory by a validated analytical method.
| h*ng/mL | ENZ215 | EU Sourced Prolia | US Licensed Prolia |
|---|---|---|---|
| Area Under the Drug Concentration-time Curve From Day 0 to Day 270 (AUC0-t) of ENZ215, EU- and US-sourced Prolia®. and EU- and US-sourced Prolia® | 7508134.18 ± 36.8 | 7674912.81 ± 24.9 | 7842297.13 ± 28.8 |
A total of twenty four blood PK samples of 2.5 mL each were collected from each subject in the study. Pre-dose sample were collected within 30 minutes prior to IP administration. Post-dose samples up to Day 2 were collected within ± 10 minutes, within ± 2 hours from Day 3 to Day 21, within ± 1 day on Day 28, within ± 3 days from Day 42 to Day 180 and within ±5 days from Day 224 to Day 270. Serum concentrations of denosumab were measured at central laboratory by a validated analytical method.
| h*ng/mL | ENZ215 | EU Sourced Prolia | US Sourced Prolia |
|---|---|---|---|
| Area Under the Drug Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of ENZ215, EU- and US-sourced Prolia®. and EU- and US-sourced Prolia® | 7622698.42 ± 36.4 | 7779487.60 ± 24.7 | 7934699.65 ± 28.9 |
AUC0-28 days were compared between ENZ215 and Prolia® using tests after log-transformation wherever appropriate.
| h*ng/mL | ENZ215 | EU Sourced Prolia | US Sourced Prolia |
|---|---|---|---|
| Partial Area Under the Drug Concentration-time Curve From Time 0 (Pre-dose) to Day 28 | 3608894.44 ± 28.9 | 3721138.61 ± 20.6 | 3796048.41 ± 22.5 |
The non-parametric analysis was used for the comparison of tmax between ENZ215 and Prolia®.
| hours | ENZ215 | EU Sourced Prolia | US Sourced Prolia |
|---|---|---|---|
| Time to Reach Cmax (Tmax) | 120.62 (47.22 to 360.63) | 120.08 (46.93 to 359.75) | 120.28 (46.98 to 479.92) |
t1/2 was compared between ENZ215 and Prolia® using tests after log-transformation wherever appropriate.
| hours | ENZ215 | EU Sourced Prolia | US Sourced Prolia |
|---|---|---|---|
| Terminal Elimination Half-life (t1/2) | 450.745 ± 28.3 | 450.207 ± 23.2 | 441.262 ± 27.1 |
CL/F was compared between ENZ215 and Prolia® using tests after log-transformation wherever appropriate.
| mL/h | ENZ215 | EU Sourced Prolia | US Sourced Prolia |
|---|---|---|---|
| Apparent Systemic Clearance (CL/F) | 0.008 ± 36.4 | 0.008 ± 24.7 | 0.008 ± 28.9 |
The AUEC was calculated as the area under the effect curve from baseline until CTX-1 values return to baseline for the first time. A total of sixteen (16) blood samples for serum CTX-1 estimation of 3.5 mL each was collected from each subject in the study. For CTX-1, blood samples were collected at the same time and after a minimum of 10 hours of fasting.
| h*% | ENZ215 | EU Sourced Prolia | US Sourced Prolia |
|---|---|---|---|
| Area Under the Effect Curve (AUEC) From Time 0 to Day 270 for Serum CTX-1 Percent Inhibition Percent Inhibition | 432174.780 ± 20.1 | 442806.204 ± 13.6 | 436622.000 ± 18.6 |
A total of 10 blood Immunogenicity assessment samples of 5.0 mL for NAb and ADA were collected from each subject in the study. The frequency and percentage of positive ADA or NAb result was provided. The proportion of positive ADA or NAb in each treatment group was compared using chi-square or Fisher's exact tests. The p-value, relative risk, and corresponding 95% CI was presented.
| participants | ENZ215 | EU Sourced Prolia | US Sourced Prolia |
|---|---|---|---|
| ADA positive subjects | 68 | 69 | 69 |
| nAb positive subjects | 3 | 3 | 2 |
Adverse events and SAEs as and when occurred, were properly recorded, evaluated, managed, and reported from signing informed consent till end of Study Assessment visit. All AEs were summarized using appropriate medical coding dictionary.
| Participants | ENZ215 | EU Sourced Prolia | US Sourced Prolia |
|---|---|---|---|
| Incidence of Adverse Events | 28 | 39 | 32 |
Collected over from signing of informed consent to 270 days that is end of study. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ENZ215 | 0/68 (0%) | 0/68 (0%) | 28/68 (41.2%) |
| EU Sourced Prolia® | 0/69 (0%) | 1/69 (1.4%) | 39/69 (56.5%) |
| US Licensed Prolia® | 0/69 (0%) | 0/69 (0%) | 32/69 (46.4%) |
| Event | ENZ215 | EU Sourced Prolia® | US Licensed Prolia® |
|---|---|---|---|
| Ligament ruptureInjury, poisoning and procedural complications | 0/68 | 1/69 | 0/69 |
| Event | ENZ215 | EU Sourced Prolia® | US Licensed Prolia® |
|---|---|---|---|
| HeadacheNervous system disorders | 9/68 | 9/69 | 14/69 |
| NasopharyngitisInfections and infestations | 6/68 | 11/69 | 13/69 |
| Upper Respiratory Tract InfectionInfections and infestations | 3/68 | 7/69 | 1/69 |
| SARS-CoV-2 test positiveInvestigations | 2/68 | 6/69 | 1/69 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/68 | 4/69 | 0/69 |
| HypocalcaemiaMetabolism and nutrition disorders | 3/68 | 3/69 | 2/69 |
| RashSkin and subcutaneous tissue disorders | 3/68 | 0/69 | 0/69 |
| ToothacheGastrointestinal disorders | 0/68 | 3/69 | 1/69 |
| Skin abrasionInjury, poisoning and procedural complications | 0/68 | 3/69 | 0/69 |
| InfluenzaInfections and infestations | 2/68 | 0/69 | 0/69 |
Participants were healthy adult male volunteers between 28 to 55 years of age.
| Age, Continuous(Years) | ENZ215 | EU Sourced Prolia | US Licensed Prolia | Total |
|---|---|---|---|---|
| Mean | 37.9 ± 8.1 | 38.9 ± 7.7 | 40.1 ± 7.8 | 39.0 ± 7.9 |
| Sex: Female, Male(Participants) | ENZ215 | EU Sourced Prolia | US Licensed Prolia | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 68 | 69 | 70 | 207 |
| Race/Ethnicity, Customized(Participants) | ENZ215 | EU Sourced Prolia | US Licensed Prolia | Total |
|---|---|---|---|---|
| Asian | 1 | 0 | 0 | 1 |
| White | 67 | 69 | 70 | 206 |
| Height(cm) | ENZ215 | EU Sourced Prolia | US Licensed Prolia | Total |
|---|---|---|---|---|
| Mean | 178.39 ± 6.22 | 178.96 ± 6.44 | 178.41 ± 7.69 | 178.59 ± 6.79 |
| BMI(kg/m^2) | ENZ215 | EU Sourced Prolia | US Licensed Prolia | Total |
|---|---|---|---|---|
| Mean | 26.219 ± 2.601 | 26.260 ± 2.760 | 25.562 ± 2.835 | 26.010 ± 2.740 |
| Weight(kg) | ENZ215 | EU Sourced Prolia | US Licensed Prolia | Total |
|---|---|---|---|---|
| Mean | 83.62 ± 10.75 | 84.16 ± 10.34 | 81.56 ± 11.67 | 83.10 ± 10.94 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2022 to primary completion in May 2024, 28 months.
Results were first posted in Dec 2025, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Enzene Biosciences Ltd.